Jonathan Jay Mazelsky - Dec 4, 2023 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
President and CEO, Director
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky
Stock symbol
IDXX
Transactions as of
Dec 4, 2023
Transactions value $
-$2,589,304
Form type
4
Date filed
12/6/2023, 05:01 PM
Previous filing
Oct 16, 2023
Next filing
Jan 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Options Exercise $1.07M +13.4K +18.4% $79.54* 86.4K Dec 4, 2023 Direct F1
transaction IDXX Common Stock Sale -$2.98M -5.8K -6.72% $512.95 80.6K Dec 4, 2023 Direct F2
transaction IDXX Common Stock Sale -$680K -1.32K -1.64% $513.51 79.2K Dec 4, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -13.4K -100% 0 Dec 4, 2023 Common Stock 13.4K $79.54 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 12 shares purchased under the Issuer's Employee Stock Purchase Plan on September 29, 2023.
F2 Represents the weighted average price of the shares sold ranging from a low of $512.35 to a high of $513.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3 Represents the weighted average price of the shares sold ranging from a low of $513.36 to a high of $513.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4 Grant of option to buy 13,424 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F5 Not applicable.